IDEAYA BIOSCIENCES RSS Feed | Nachrichten - www.finanzen.net

Stocks in Action USA: IDEAYA Biosciences, Leggett & Platt, Revolution Medicines

Mon, 13 Apr 2026 17:43:50 +0200

IDEAYA Biosciences (IDYA) – Onkologiespezialist gelingt klinischer Durchbruch: Aktienexplosion nach überzeugenden Studiendaten bei Augenkrebs-Therapie!Die Aktie von IDEAYA Biosciences steht zum Wochenstart massiv im Fokus der Anleger, nachdem das Unternehmen ...

IDEAYA Biosciences hat die Zahlen zum jüngsten Quartal vorgelegt

Wed, 18 Feb 2026 06:35:06 +0100

IDEAYA Biosciences hat am 17.02.2026 Zahlen zum jüngsten Quartal vorgelegt, das am 31.12.2025 endete.Der Verlust je Aktie belief sich auf 0,94 USD. Im Vorjahresquartal waren -1,490 USD je Aktie in den Büchern ...

IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference

Sun, 11 Jan 2026 18:00:00 +0100

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a ...

IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference

Mon, 05 Jan 2026 12:00:00 +0100

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision ...

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uve...

Thu, 11 Dec 2025 12:00:00 +0100

Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trial
Topline data, including median PFS, are expected in 1Q 2026 to support ...

IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers

Wed, 10 Dec 2025 12:00:00 +0100

Phase 1 dose escalation trial of monotherapy IDE574 expected to begin in 1Q 2026
Targeting to present preclinical data detailing pharmacologic profile and evidence of anti-tumor activity ...

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

Mon, 01 Dec 2025 12:00:00 +0100

B7H3 and PTK7 is co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers, at approximately 30%, 46%, and 27%, respectively
Deep and durable regressions ...

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 28 Nov 2025 12:00:00 +0100

SOUTH SAN FRANCISCO, Calif., Nov. 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a ...

IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events

Mon, 24 Nov 2025 12:00:00 +0100

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a ...

IDEAYA Biosciences: Bilanzvorlage zum letzten Quartal

Thu, 06 Nov 2025 06:35:06 +0100

IDEAYA Biosciences äußerte sich am 04.11.2025 zu den Geschäftsergebnissen des am 30.09.2025 abgelaufenen Quartals.Es wurde ein Gewinn je Aktie von 1,35 USD ausgewiesen. Im Vorjahresquartal war ein Gewinn ...